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Abstract 
Purpose: Dosimetry for 90Y microsphere therapies (YMT) 
with Standard (SM) and Partition (PM) models provide only 
uniform dose estimates to tumor and liver. Our objective is 
to calculate tumor dose heterogeneity, known to effect re-
sponse, using voxel-based dosimetry and investigate the lim-
itations of SM and PM. 
 
Methods: Voxel-based dosimetry was performed on 17 YMT 
patients using Monte Carlo DOSXYZnrc. 90Y activity and 
tissue/density distributions were based on quantitative 90Y 
bremsstrahlung SPECT/CT. Tumors (n=31), liver, and treat-
ment lobe/segments were segmented on diagnostic CT or 
MR. Dose volume histograms (DVH) were created for tu-
mors and normal liver. Bland-Altman analysis compared 
voxel-based mean absorbed doses to tumor and liver with 
SM and PM. Tumor and normal liver absorbed dose hetero-
geneity were investigated through metrics: integral uni-
formity (IU), D10/D90, COV. Correlations of heterogeneity 
with voxel-based mean doses and volumes were evaluated.  
 
Results: Heterogeneity metrics (mean ± 1σ) for tumor dose 
were COV = 0.48 ± 0.28, D10/D90 = 4.7 ± 3.9, and IU = 0.8 ± 
0.18. Heterogeneity metrics correlated with tumor volume (r 
> 0.58) but not tumor mean doses (r < 0.20). Voxel-based 
tumor mean doses correlated with PM (r = 0.84) but not SM 
(r = 0.08). Both yielded poor limits of agreement with of 83 ± 
174 and -28 ± 181 Gy, respectively. Normal liver heterogene-
ity metrics (mean ± 1σ) were COV = 0.83 ± 0.29, D10/D90 =  
12 ± 15, and IU = 0.97 ± 0.03. Only D10/D90 (r = 0.49) corre-
lated with mean normal liver absorbed dose. Voxel-based 
normal liver/lobe mean doses correlated with PM (r = 0.96), 
but had poor limits of agreement (26 ± 29 Gy). 
 
Conclusion: Tumor doses have high levels of heterogeneity 
that increase with volume but are independent of dose. 
Voxel-based DVH and dose heterogeneity metrics will pro-
mote accurate characterization of tumor response following 
YMT. 
[Research Support: NIH/NCI R01 CA138986] 
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Key Results:  
 
FIG. 1: This figure shows the tumor dose heterogeneity (max 
to min range of individual absorbed dose tumor estimates in 
beige shadow), together with the mean voxel-based tumor 
absorbed dose (red) and those for the PM (blue) and SM 
(green).  
High levels of heterogeneity are observed. The PM and SM are 
unable to encompass the heterogeneity which is represented 
as the shaded area for each tumor. The PM tracks the mean 
voxel-based dose better than the SM. Unfortunately, the PM 
overestimates for 28/31 with a large mean difference of 83 ± 
174 Gy. 
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FIG. 2: A plot of mean tumor voxel-based dose versus those from PM and SM showing that the PM is a better surrogate for true mean doses 
than the SM. No correlation between voxel-based and SM was found. Voxel-based and PM were correlated, but notice that the PM overesti-
mates the true mean dose by a factor of ~2.
 
TABLE 1: Correlations of heterogeneity metrics with voxel-based mean absorbed doses. Checkered cells indicate that no correlation was found. 
D10 and D90 are derived from cumulative dose volume histograms. D90 is the minimum dose in the hottest 90% of tumor volume. Similarly, 




Linear fits of heterogeneity metrics (correlation coefficient) 
versus voxel-based mean dose (Gy) versus volume (cc) 
tumor (N=31) 
y = mx + b (corr coef) 
normal liver (N=17) 
y = mx + b (corr coef) 
tumor (N=31) 
y = mx + b (corr coef) 
normal liver (N=17) 
y = mx + b (corr coef) 
COV   7.0E-4x + 0.34 (0.68)  
max/min 2.0E-1x + 15 (0.32) 
D10/D90 4.1E-1x – 3.6 (0.49) 9.4E-3x + 2.7 (0.64) -9.6E-3x + 25 (0.44) 
IU  4.0E-4x + 0.71 (0.59)  
 
 
TABLE 2: Bland Altman analyses of dosimetry models with voxel-based mean absorbed dose as truth. Biases calculated as PM or SM minus 
voxel-based mean absorbed dose. Both SM and PM overestimate the normal liver dose compared to voxel-based means. 
 Bland Altman analysis with voxel-based mean dose as 
truth 
tumor (N=31) 
bias ± 2σ (Gy) 
normal liver (N=17) 
bias ± 2σ (Gy) 
Standard Model -28.1 ± 180.7 40.1 ± 26.8 
Partition Model 83.4 ± 174.4 25.7 ± 29.3 
 
 
 
 
